46例早期胃癌凝集素免疫组化研究

本文收集我科1982年至1993年400多例胃癌切除标本中所有46例早期胃癌病例，选用Con-A、PNA，LCA、DBA五种凝集素采用ABC法对46例早期胃癌进行标记，观察五种凝集素在胃癌组织、癌旁肠化上皮杯状细胞，癌旁不典型增生上皮、正常胃粘膜上皮、胃底腺和幽门腺中的分布，总结出DNA在胃癌组织中分布百分比最高，五种凝集素在癌旁肠化杯状细胞和癌旁不典型增生上皮中的分布没有特异性。     

食管鳞状细胞癌组织中核干细胞因子蛋白和mRNA的半定量表达

目的 探讨食管鳞状细胞癌组织中核干细胞因子(NS)蛋白和mRNA的半定量表达情况.方法 应用免疫组化SABC法和逆转录聚合酶链反应(RT-PCR)法,检测62例食管鳞状细胞癌组织及其相对应的31例癌旁不典型增生组织和62例正常食管黏膜组织中NS蛋白和mRNA的半定量表达情况.结果 正常食管黏膜组织、癌旁不典型增生组织和食管鳞状细胞癌组织中,NS蛋白阳性表达率分别为17.7%(11/62)、41.9%(13/31)和69.4%(43/62),组间比较,差异有统计学意义(χ2=33.676,P＜0.01).食管鳞状细胞癌组织中,NS蛋白阳性表达率与其组织学分级、侵袭程度及淋巴结转移密切相关(均为P＜0.05),而与年龄、性别和病理分型无关(均为P＞0.05).食管鳞状细胞癌组织中,NS mRNA的相对含量(0.971±0.121)高于癌旁不典型增生组织(0.913±0.085)和正常食管黏膜组织(0.866±0.103),组间比较,差异有统计学意义(F=14.829,P＜0.01).不同组织学分级、不同侵袭程度及有无淋巴结转移的食管鳞状细胞癌组织之间,NS mRNA的相对含量差异均有统计学意义(均为P＜0.05),NSmRNA的相对含量与年龄、性别和病理分型无关(均为P＞0.05).结论 食管鳞状细胞癌组织中,NS mRNA的表达升高,其高表达与食管鳞状细胞癌的发生发展有关.     

胃癌及癌前病变组织中MUC5AC基因的异常表达及意义

目的：揭示正常胃粘膜、癌前病变和胃癌组织中ＭＵＣ５ＡＣ基因的表达与其临床病理分型之间的联系。方法：应用免疫组织ＳＰ法检测人正常胃粘膜、癌前病变粘膜以及胃癌组织中ＭＵＣ５ＡＣ核蛋白的表达。结果：人正常胃中的浅表１／３范围内广泛分布ＭＵＣ５ＡＣ基因产物（１００％）,肠化、不典型增生和胃癌组织中的表达阳性率分别是２９．６％、１００％和４０．０％。胃癌组织中ＭＵＣ５ＡＣ核粘蛋白的表达与胃癌患者的性别、肿瘤     

Survivin在早期胃癌及癌前病变组织中的表达及其与PTEN表达的关系

目的 探讨Survivin在早期胃癌及癌前病变组织中的表达及其与PTEN表达的关系.方法 采用免疫组化SABC法检测Survivin、PTEN基因蛋白在30例正常胃黏膜、20例不完全型大肠化生,93例轻、中、重度不典型增生、54例早期胃癌组织中的表达.结果 Survivin在正常胃黏膜中不表达(0/30),在不完全型大肠化生中的阳性表达率为5.00%(1/20);在轻、中、重度不典型增生的阳性率分别为6.25%(2/32)、8.57%(3/35)和65.73%(17/26),其中轻、中度不典型增生与重度不典型增生的差异有显著性(P＜0.05).在早期胃癌组织中阳性表达率为68.51%(37/54).Survivin和PTEN基因蛋白在早期胃癌组织中的表达呈明显负相关γ=-0.564,P=0.0000.结论 Survivin在早期胃癌组织中表达上调,说明该基因在早期胃癌的发生过程中可能起重要作用,Survivin表达越高,早期胃癌的分化程度越低.早期胃癌中Survivin中的阳性表达与PTEN阳性表达密切相关.     

食管鳞状细胞癌组织中KiSS-1和MMP-2的表达及其相关性研究

目的 检测食管鳞状细胞癌组织中KiSS-1和MMP-2蛋白的表达及其相关性,探讨二者与食管鳞状细胞癌浸润转移的关系.方法 应用免疫组织化学S-P法检测62例食管鳞状细胞癌、31例癌旁不典型增生及62例正常食管黏膜组织中KiSS-1及MMP-2蛋白的表达.结果 食管鳞状细胞癌、癌旁不典型增生及正常食管黏膜组织中KiSS-1蛋白的阳性表达率分别为56.5%、67.7%和90.3%(P<0.05);食管鳞状细胞癌组织中KiSS-1蛋白阳性表达率与患者的性别、年龄及肿瘤的组织学分级无关(P>0.05),而与浸润深度及淋巴结转移密切相关(P<0.05).食管鳞状细胞癌、癌旁不典型增生及正常食管黏膜组织中MMP-2蛋白的阳性表达率分别为71.0%、54.8%和22.6%(P<0.05);食管鳞状细胞癌组织中MMP-2蛋白的阳性表达率与肿瘤的分化程度、浸润深度及有无淋巴结转移有关(P<0.05),而与患者的性别、年龄无关(P>0.05).食管鳞状细胞癌组织中KiSS-1及MMP-2蛋白的表达呈负相关(rs=-0.418).结论 KiSS-1对食管鳞状细胞癌的浸润及转移有抑制作用;MMP-2则对食管鳞状细胞癌的转移有促进作用,联合检测KiSS-1和MMP-2蛋白的表达有望成为判定食管鳞状细胞癌浸润及转移能力的重要指标之一.     

Pi类谷胱甘肽S转移酶在胃粘膜肠上皮化生中的表达

目的检测Pi类谷胱甘肽S转移酶(GST-π)在癌前肠化粘膜和胃癌组织中的表达,探讨GST-π在胃癌发生过程中的作用.方法利用HID-ABpH2.5-PAS粘蛋白组织化学染色方法和S-P免疫组织化学技术对30例正常胃粘膜、82例肠化粘膜、18例胃癌组织进行GST-π检测.结果在正常胃粘膜中未见GST-π的表达,肠化粘膜GST-π阳性率为85.4%,高于正常胃粘膜(P＜0.01),在Ⅰ、Ⅱ、Ⅲ型肠化中GST-π表达逐渐降低,分别为92.3%、87.0%、78.3%.在胃癌中GST-π阳性率为44.4%,高于正常胃粘膜(P＜0.01),低于肠化粘膜(P＜0.01).结论GST-π表达的变化与胃癌发生发展密切相关,是胃癌发生的"早期事件".     

p53在胃粘膜上皮不典型增生、胃癌中的表达及意

目的研究p53胃粘膜上皮不典型增生、早期胃癌及进展期胃癌中的表达及临床意义.方法使用抗p53蛋白的单克隆抗体Do-7对196例胃癌,59例胃粘膜不典型增生,37例早期胃癌组织p53的表达进行免疫组化研究.结果p53在轻度不典型增生,中度不典型增生,重度不典型增生,早期胃癌,进展期胃癌表达率分别为6.7%、10.5%、48.0%、48.6%、50.5%.结论胃粘膜上皮轻度、中度不典型增生表达较低,而在重度不典型增生,早期胃癌和进展期胃癌中有较高表达.表明p53在胃粘膜上皮癌发生、发展中起作用,且p53异常表达是胃癌发生的早期事件,与胃癌发生有关.     

p53在胃粘膜上皮不典型增生、胃癌中的表达及意义

目的 研究p53胃粘膜上皮不典型增生,早期胃癌及进展期胃癌中的表达及临床意义。方法 使用抗p53蛋白的单克隆抗体Do-7对196例胃癌,59例胃粘膜不典型增生,37例早期胃癌组织p53的表达进行免疫组化研究。结果 p53在轻度不典型增生,中度不典型增生,重度不典型增生,早期胃癌,进展期胃癌表达率分别为6.7%、10.5%、48.0%、48.6%、50.5%.结论 胃粘膜上皮轻度\中度不典型增生表达较低,而在重度不典型增生,早期胃癌和进展期胃癌中有较高表达,表明p53在胃粘膜上皮癌发生,发展中起作用,且p53异常表达是胃癌发生的早期事件,与胃癌发生有关.     

长链非编码RNA XLOC_002319在贲门腺癌中的表达及其甲基化状态

[目的]检测贲门腺癌(GCA)中长链非编码RNA XLOC_002319(lncRNA XLOC_002319)的表达及其甲基化状态,探讨XLOC _002319在贲门腺癌发生发展中的作用.[方法]分别应用实时荧光定量聚合酶链反应(qRT-PCR)以及甲基化特异性PCR(MSP)检测贲门腺癌组织、癌旁不典型增生组织及癌旁正常组织中XLOC_ 002319的表达和甲基化状态.[结果]XLOC_002319在贲门腺癌组织和癌旁不典型增生组织中的表达显著低于癌旁正常组织(P＜0.01),并且在贲门腺癌组织中XLOC_ 002319的表达与组织学分化程度、淋巴结转移和TNM分期密切相关(P＜0.05).贲门腺癌组织中XLOC _002319的启动子区甲基化率(61.54％)和癌旁不典型增生组织甲基化率(54.84％)显著高于癌旁正常组织(17.95％)(P＜0.01),并且贲门腺癌组织中XLOC_002319的启动子区甲基化率与组织学分化程度、淋巴结转移和TNM分期密切相关(P＜0.05).发生XLOC_002319甲基化的贲门腺癌组织中XLOC_002319的表达显著低于未发生甲基化的贲门腺癌组织(0.217±0.074 vs 0.253±0.060,P＜0.05).[结论]XLOC_002319在贲门腺癌中的异常低表达可能与贲门腺癌的发生密切相关,且其启动子区甲基化可能是导致其表达沉默的机制之一.     

Ⅱ型环氧合酶和CDK4在食管鳞癌中的表达及意义

目的 探讨Ⅱ型环氧合酶(COX-2)和CDK4在食管鳞癌中的表达与食管鳞癌的发生、浸润及转移的关系.方法 采用免疫组化S-P法检测49例食管鳞癌及癌旁黏膜组织中的表达.结果 COX-2在癌旁正常上皮、单纯增生上皮、轻度不典型增生上皮、重度不典型增生上皮、原位癌和浸润癌组织中的阳性表达率分别为0%(0/25)、7.1%(2/28)、33.3%(7/21)、50.0%(5/10)、69.2%(9/13)和73.5%(36/49).正常上皮组织与单纯增生上皮比较差异没有统计学意义(P＞0.05),但与轻度不典型增生上皮、重度不典型增生上皮、原位癌和浸润癌组织比较差异有统计学意义(P＜0.01).其在食管鳞癌中的阳性率与癌组织分级有关(P＜0.05).CDK4蛋白在癌旁正常上皮、单纯增生上皮、轻度不典型增生上皮、重度不典型增生上皮、原位癌和浸润癌组织中的阳性表达率分别为8%(2/25)、21.4%(6/28)、42.9%(9/21)、70%(7/10)、61.5%(8/13)和91.8%(45/49).正常上皮组织与单纯增生上皮比较差异没有统计学意义(P＞0.05),但与轻度不典型增生上皮、重度不典型增生上皮、原位癌和浸润癌组织比较差异有统计学意义(P＜0.01).CDK4阳性率与鳞癌分级无关(P＞0.05).COX-2、CDK4蛋白表达与食管鳞癌的浸润深度和淋巴结转移无关(P＞0.05).食管鳞癌组织中COX-2、CDK4蛋白阳性率有正相关性(P＜0.01).结论 COX-2、CDK4蛋白表达与食管鳞癌的发生有关.     

Mucin gene expression and cell differentiation in human normal, premalignant and malignant esophagus

Esophageal carcinoma includes squamous cell carcinoma and Barrett's adenocarcinoma. The latter usually develops from a premalignant lesion named Barrett's esophagus. MUC genes are known to be specifically expressed in the normal, premalignant and malignant epithelia of various tissues. The aim of this study was to establish the pattern of MUC gene expression in the esophageal mucosa under normal conditions, and under pathological conditions such as squamous cell carcinoma, Barrett's esophagus and adenocarcinoma. Samples of esophageal control mucosa, metaplastic and malignant tissues were obtained from 40 patients undergoing esophagectomy for squamous cell carcinoma (n = 17), or Barrett's esophagus with adenocarcinoma (n = 23). In situ hybridization and northern blot were used with probes specific for the MUC1, MUC2, MUC3, MUC4, MUC5AC, MUC5B, MUC6 and MUC7 genes to assess their expression in these samples. Submucosal glands of control esophageal mucosa expressed MUC5B, whereas MUC1 and MUC4 were found in both control epithelium and squamous cell carcinoma. MUC4 expression correlated with squamous cell differentiation. Barrett's adenocarcinoma exhibited various patterns of MUC gene expression, the strongest being in the well-differentiated mucinous adenocarcinomas. Barrett's metaplasia was also associated with a specific MUC gene expression pattern, since the gastric apomucin mRNAs, MUC5AC and MUC6, were expressed in gastric metaplasia, and the intestinal apomucin mRNAs, MUC3, MUC4 and mostly MUC2, in intestinal metaplasia. Residual expression of gastric apomucin mRNAs was found in intestinal metaplasia. From these results, we conclude that MUC genes can be considered reliable phenotypic markers of the esophageal cell differentiation, thus providing new insight into the development of Barrett's esophagus.     

组织芯片检测p16蛋白在不同胃组织中的表达意义

[目的]分析胃癌相关差异表达蛋白p16在不同胃组织中的表达意义,为临床早期发现胃癌及评估胃癌患者预后提供有价值的资料.[方法]采用免疫组织化学染色,检测胃组织芯片(包括正常胃黏膜、癌旁、非典型增生、胃癌及淋巴结转移癌组织)中p16蛋白的表达,分析其在胃癌组织中表达与临床病理特征的关系.[结果] p16蛋白在正常胃黏膜、癌旁、非典型增生和胃癌组织中的表达率分别为76.47％ (26/34)、79.59％( 39/49)、34.62％ (9/26)和8.64％(7/81);p16蛋白在胃癌组织中阳性表达率较正常胃黏膜、癌旁组织和非典型增生组织降低(P＜0.01),而非典型增生组织中阳性表达率较正常胃黏膜和癌旁组织降低(P＜0.05);p16蛋白表达与胃癌患者年龄、肿块大小和淋巴结转移有关(P＜0.05).[结论] p16蛋白表达与胃癌的发生发展、患者年龄、肿块大小及淋巴结转移有关.     

Rsf-1在胃癌和癌前病变组织中的表达及临床意义

目的:染色质重塑因子1(chromatin remodeling factor 1,Rsf-1)可作为肿瘤靶向治疗的靶点,因此探讨其在胃癌(gastric cancer)及癌前病变(precancerous lesions)组织中的表达及临床意义。方法:采用免疫组化SP法检测30例萎缩性胃炎、30例肠上皮化生、22例不典型增生Rsf-1蛋白表达水平。并检测64例胃癌与配对癌旁组织(手术切缘距离肿瘤>5 cm)中Rsf-1和p53蛋白表达水平并分别分析与胃癌临床病理参数间的关系,同时分析Rsf-1与p53在胃癌中表达的相关性。结果:Rsf-1在胃癌、肠上皮化生、不典型增生组织中的阳性表达率均高于癌旁组织(P＜0.05)。Rsf-1在胃癌中表达与淋巴结转移有关(P＜0.05）。p53在胃癌中的阳性表达率高于癌旁组织,其表达与淋巴结转移有关(P＜0.05)。p53和Rsf-1在胃癌中的表达存在正相关性(r=0.38,P＜0.05),两者在胃癌中共阳性表达与淋巴结转移有关（P＜0.05)。结论:Rsf-1可能参与了胃癌病变的发生及发展,对胃癌早期筛查具有重要指导意义。Rsf-1和p53两者共阳性表达对于预测胃癌淋巴结转移可能具有一定的参考价值。     

胃癌和癌旁黏膜中ST—4—39抗原表达的研究

目的 检测胃癌和癌旁黏膜中ST-4-39抗原的表达,并探讨其表达与胃癌生物学特性的关系。方法 标本包括10例正常黏膜、20例肠化生黏膜、45例癌旁不典型增生黏膜和79例胃癌组织。采用S-P法免疫组织化学技术检测各种组织中ST-4-39抗原的表达。结果 胃癌中ST-4-39抗原阳性率为68.4％(54/79),高于不典型增生组的48.9％(22/45,P<0.05)和肠上皮化生组的30.0％(6/20,P<0.01),胃正常黏膜和肉瘤中ST-4-39抗原呈阴性表达。ST-4-39抗原表达阳性率与肿瘤大小、大体分型和浆膜侵犯无关(P>0.05)。而与癌分化程度、淋巴结状态和Lauren分型相关(P<0.05)。结论 ST-4-39抗原可作为一种新的肿瘤标志物,用于胃癌和癌前病变的研究。检测ST-4-39抗原的表达对评价胃癌的早期发生、发展和预后是有价值的。     

KAI1及Caveolin-1在胃癌组织中的表达及其意义

目的探讨正常胃黏膜、不典型增生胃黏膜及胃癌组织中KAI1及Caveolin-1蛋白的表达。方法应用免疫组化SP法检测22例正常胃黏膜、65例不典型增生胃黏膜及74例胃癌组织中KAI1蛋白、Caveolin-1蛋白的表达状况。结果正常胃黏膜、不典型增生胃黏膜及胃癌组织中,KAI1和Caveolin-1阳性率呈递减趋势,且组间差异有显著性（χ2=24.022,P〈0.05;χ2=44.315,P〈0.05）。经χ2和Fisher精确概率法检验,KAI1蛋白的表达在不同浸润深度、有无淋巴结转移组、有无脉管侵犯组内表达率的差异有显著性（P〈0.05）,在年龄及性别组内表达率的差异性无显著性（P〉0.05）。Caveolin-1蛋白阳性表达率与有无淋巴结转移、浸润深度有关（P〈0.05）,而与有无脉管转移、年龄及性别（P〉0.05）无关。Spearman等级相关分析显示,KAI1蛋白与Caveolin-1蛋白表达呈正相关（rs=0.827,P〈0.05）。结论 KAI1、Caveolin-1在胃癌组织中表达的下调甚至缺失可能是胃癌发生、发展以及浸润转移的重要原因之一。     

Immunohistochemical study of MUC5AC expression in human gastric carcinomas using a novel monoclonal antibody

In order to investigate the expression of MUC5AC mucin in normal gastric mucosa and gastric carcinomas, we produced 3 monoclonal antibodies (MAbs) using a MUC5AC synthetic peptide. The immunohistochemical study was performed using one of these MAbs (CLH2) which reacted with the different designs of peptides based on the MUC5AC tandem repeat and with native and deglycosylated mucin extracted from gastric tissues. CLH2 immunoreactivity was restricted to foveolar and mucopeptic neck cells in normal gastric mucosa. No reactivity was observed in type-1 intestinal metaplasia. Out of 66 gastric carcinomas, 42 (63.6%) expressed MUC5AC. Most diffuse carcinomas were positive (83.3%), whereas only 59.3% of intestinal and 40.0% of atypical carcinomas expressed MUC5AC (p < 0.05). Gastric carcinomas with mixed pattern showed immunoreactivity in diffuse areas and decreased immunoreactivity in intestinal areas. Every early gastric carcinoma expressed MUC5AC, in contrast to 58.6% of advanced carcinomas (p < 0.05). A trend toward decreased immunoreactivity was observed in deep areas of advanced carcinomas in comparison with the respective superficial areas. Taking together the specific staining of foveolar and mucopeptic neck cells and the absence of immunoreactivity in intestinal metaplasia, we conclude that MUC5AC expression may be used as a marker of gastric differentiation. This assumption is further supported by the finding of MUC5AC immunoreactivity in most diffuse carcinomas, which usually display morphologic and histochemical signs of gastric differentiation. The expression of MUC5AC in early gastric carcinomas, regardless of their histologic type, suggests that all gastric carcinomas retain at least some cells with a gastric phenotype during the first steps of neoplastic development. Int. J. Cancer 74:112–121. © 1997 Wiley-Liss, Inc.     

Role of MUC1 and MUC5AC expressions as prognostic indicators in gastric carcinomas

BACKGROUND AND OBJECTIVES: The aim of this study is to clarify the relationship between the expression of MUC1 and MUC5AC mucins and the clinicopathological features in human gastric carcinomas using the mouse monoclonal antibodies VU-4H5 and Clone 45M1, respectively. Furthermore, the possibility of using phenotypes (MUC1+/MUC5AC+, MUC1+/MUC5AC-, MUC1-/MUC5AC-, MUC1-/MUC5AC+) to predict prognosis of the patients is evaluated. METHODS: Formalin-fixed, paraffin wax-embedded tissues from 76 cases of gastric cancer were examined for the expression of MUC1 and MUC5AC mucin antigens immunohistochemically using the avidin-biotin-peroxidase method. RESULTS: Of the 76 cases, MUC1 and MUC5AC immunoreactivities were observed in 49 (64.5%) and in 32 (42.1%) of gastric carcinoma tissues, respectively. MUC1 expression was significantly correlated to the depth of invasion, lymph node metastasis, peritoneal dissemination, and tumor stage. On the other hand, MUC5AC was inversely associated with depth of invasion, lymph node metastasis, liver metastasis, and tumor stage. Multivariate analyses indicated that tumor stage and MUC1 mucin expression were independently correlated with overall survival. The patients with MUC1+/MUC5AC- antigen staining in carcinoma tissues showed the lowest survival rate among four phenotypes. In contrast, the patients with MUC1-/MUC5AC+ antigen staining in carcinoma tissues showed the highest survival rate. CONCLUSIONS: Altogether these data suggest that combined evaluation of MUC1 and MUC5AC mucin staining may be clinically helpful to predict outcome in patients with gastric cancer.     

Diagnostic utility of mucin profile in fine-needle aspiration specimens of the pancreas: an immunohistochemical study with surgical pathology correlation

BACKGROUND: The cytologic differentiation between neoplastic and reactive/reparative processes in the endoscopic ultrasound-guided fine-needle aspirations (EUS-FNA) of the pancreas can be difficult. Malignant transformation of the pancreatic ductal epithelium changes the expression of apomucins. The goal of the current study was to determine an optimal immunohistochemical panel of mucin (MUC) antibodies that would allow the cytomorphologic distinction of pancreatic ductal adenocarcinoma and its differentiation from reactive/reparative processes and inadvertently sampled gastric and duodenal mucosa. METHODS: Pancreatic EUS-FNA specimens performed on 351 patients were reviewed. Expression profiles of MUC1, 2, 5AC, and 6 were examined on 56 cell block sections and 26 follow-up pancreatectomy specimens. RESULTS: MUC1 and 6 expression was found in nonneoplastic pancreatic samples, whereas there was an absence of expression of MUC2 and 5AC. MUC2 was detected in mucosal goblets cells of the duodenum, MUC6 in Brunner glands, and MUC5AC in gastric foveolar cells. MUC5AC expression in differentiating ductal adenocarcinomas from benign conditions demonstrated better operating characteristics than either MUC1 or MUC6. The apomucin expression pattern both in cytology and follow-up surgical pathology specimens was similar. In surgical pathology specimens, the panel of 3 antibodies, MUC1+/MUC2-/MUC5AC+, was noted in 15 of 17 ductal carcinomas (88.2%). In nonneoplastic pancreatic tissue, the expression panel MUC1+/MUC2-/MUC5AC- was observed in 14 of 17 (82.4%) cases. In cytology specimens, the combination of MUC1+/MUC2-/MUC5AC+ was noted in 21 of 30 ductal carcinoma cases (70.0%), 3 of 6 atypical cases (50%), and 1 of 1 suspicious for malignancy cases (100%). The combination MUC1+/MUC2-/MUC5AC+ was not observed in any of the negative for malignancy or reactive cases (0 of 6). CONCLUSIONS: The most optimal panel for the diagnosis of ductal adenocarcinoma in both the EUS-FNA specimens is a panel including MUC1/MUC2/MUC5AC, whereas a panel of all 4 antibodies (MUC1, 2, 5AC, and 6) will in addition aid in differentiating inadvertently sampled normal/reactive duodenal and gastric epithelium from neoplastic pancreatic tissue.     

Caveolin-1在胃癌组织中的表达及临床生物学意义

背景与目的:Caveolin-1作为候选抑癌基因,在多种肿瘤均有异常表达。本研究探讨Caveolin-1在非癌胃粘膜、肠上皮化生、异型增生和胃癌组织以及胃癌细胞系MGC803和BGC823的表达特点。方法:采用冰冻组织微阵列的免疫组织化学(immunohistochemistry,IHC)染色,在完全相同的实验条件下检测56例胃癌及29例非癌粘膜、11例肠上皮化生、7例异型增生组织中Caveolin-1的表达状况,及其与胃癌的临床病理分期、淋巴结转移、Lauren分型及组织学分型的关系。Westernblot和RT-PCR法检测胃癌及相应癌旁组织与MGC-803和BGC-823细胞中Caveolin-1蛋白和RNA的表达情况。结果:免疫组化结果显示,Caveolin-1在非癌胃粘膜、肠上皮化生、异型增生和胃癌中的阳性率分别为86.2%(25/29)、81.8%(9/11)、57.1%(4/7)、17.9%(10/56);胃癌与其它各组间的阳性率有显著性差异(P<0.05)。进展期胃癌的Caveolin-1阳性率(16.0%)低于早期胃癌(33.3%),但无统计学意义(P>0.05)。弥漫型胃癌的阳性率(7.0%)明显低于肠型胃癌(26.9%,P<0.05)。有淋巴结转移的胃癌Caveolin-1阳性率(9.7%)低于无淋巴结转移(31.8%,P<0.05)。Westernblot及RT-PCR结果显示,胃癌组织和相应非癌胃粘膜组织中Caveolin-1的表达无显著性差异,但MGC-803和BGC-823细胞中Caveolin-1表达